EP3068393
SAMSETT MEÐFERÐ SEM FELUR Í SÉR MDM2 HEMIL OG EITT EÐA FLEIRI LYFJAFRÆÐILEGA VIRK LYF TIL VIÐBÓTAR TIL MEÐFERÐAR Á KRABBAMEINUM
Status:
EP Einkaleyfi fallið úr gildiEP appl. date:
11.11.2014EP published:
9.3.2022EP application number:
14805743.3
EP translation filed:
1.6.2022Grant published:
15.7.2022EPO information:
European Patent Register
Max expiry date:
10.11.2034Expiry date:
10.11.2023
Title in English:
COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERSLanguage of the patent:
English
Timeline
Today
11.11.2014EP application
9.3.2022EP Publication
1.6.2022Translation submitted
15.7.2022Registration published
10.11.2023Expires
Owner
Name:
Amgen Inc.Address:
One Amgen Center Drive, Thousand Oaks, California 91320-1799, US
Inventor
Name:
CAENEPEEL, SeanAddress:
Thousand Oaks, CA 91360, US
Name:
CANON, JudeAddress:
Marina Del Rey, California 90292, US
Name:
HUGHES, PaulAddress:
Santa Monica, California 90403, US
Name:
OLINER, Jonathan D.Address:
Garrett Park, MD 20896, US
Name:
RICKLES, Richard J.Address:
Arlington, Massachusetts 02474, US
Name:
SAIKI, Anne Y.Address:
Moorpark, California 93021, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
201361902717 PDate:
11.11.2013Country:
US
Classification
Categories:
A61K 31/451, A61K 31/706, A61K 31/7068, A61P 35/02
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 21.11.2022
Expires: 10.11.2023
Payer: Árnason Faktor ehf.